Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK's Option Strategy For Human Genome Sciences' Lupus Drug Looking Smarter After BLISS-52 Win

This article was originally published in The Pink Sheet Daily

Executive Summary

Positive data from one of two Phase III trials needed for a BLA raise hopes, stock prices for the two companies.

You may also be interested in...



Benlysta Back In The Spotlight With BLISS-76, But Second Phase III Still May Not Be Enough To Support Some Claims

BLISS-76 shows Benlysta 10 mg/kg is efficacious in patients with systemic lupus erythematosus; HGS/GSK expect to file in first half 2010.

Benlysta Back In The Spotlight With BLISS-76, But Second Phase III Still May Not Be Enough To Support Some Claims

BLISS-76 shows Benlysta 10 mg/kg is efficacious in patients with systemic lupus erythematosus; HGS/GSK expect to file in first half 2010.

Outlook BLISSful For HGS' Benlysta After Full Data Released At ACR

PHILADELPHIA - The full data set for Human Genome Sciences' pivotal BLISS-52 study - presented at the American College of Rheumatology meeting on Oct. 20 - gives some indication that the firm's systemic lupus erythematosus candidate Benlysta (belimumab) could have a broader than expected commercial reach

Related Content

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel